ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
Clinical trials for ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) explained in plain language.
Never miss a new study
Get alerted when new ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) trials appear
Sign up with your email to follow new studies for ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Virtual coach for rare lung disease: does AR boost rehab?
Knowledge-focused CompletedThis study looked at whether using augmented reality (AR) can help people with Alpha-1 antitrypsin deficiency stick to a home program of breathing exercises and daily walking. Fifty adults took part, doing breathing exercises twice a day and aiming for 5,000 steps daily. The main…
Matched conditions: ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
Sponsor: University of Parma • Aim: Knowledge-focused
Last updated May 26, 2026 12:11 UTC
-
Healthy volunteers test new drug for rare lung and liver disease
Knowledge-focused CompletedThis study tested a new drug called WVE-006 in 47 healthy volunteers to see if it is safe and how the body processes it. The goal was to gather information for future trials in people with Alpha-1 Antitrypsin Deficiency, a genetic condition that can damage the lungs and liver. Pa…
Matched conditions: ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
Phase: PHASE1 • Sponsor: Wave Life Sciences Ltd. • Aim: Knowledge-focused
Last updated May 20, 2026 11:55 UTC